The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Malignant Mesothelioma Therapeutic Market Research Report 2025
Synopsis
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The global Malignant Mesothelioma Therapeutic market was valued at US$ 329.8 million in 2023 and is anticipated to reach US$ 532.5 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma Therapeutic.
Report Scope
The Malignant Mesothelioma Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Malignant Mesothelioma Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Malignant Mesothelioma Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Segment by Type
Pemetrexed
Cisplatin
Others
Segment by Application
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Malignant Mesothelioma Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (known as the mesothelium).
Malignant mesothelioma is a cancer of the thin tissue (mesothelium) that lines the lung, chest wall, and abdomen. The major risk factor for mesothelioma is asbestos exposure.
The global Malignant Mesothelioma Therapeutic market was valued at US$ 329.8 million in 2023 and is anticipated to reach US$ 532.5 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The classification of Malignant Mesothelioma Therapeutic includes Pemetrexed, Cisplatin and others. The proportion of Pemetrexed in 2019 approaches 50%. Malignant Mesothelioma Therapeutic is mostly used for Pleural Mesothelioma, and the proportion in 2019 is about 80%. Europe is the largest market, with a sales market share above 50% in 2019. Following Europe, Asia Pacific is the second largest sales place with the sales market share of above 1/5. Market competition is intense. Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.
This report aims to provide a comprehensive presentation of the global market for Malignant Mesothelioma Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Malignant Mesothelioma Therapeutic.
Report Scope
The Malignant Mesothelioma Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Malignant Mesothelioma Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Malignant Mesothelioma Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly
Teva
Sanofi
Bristol-Myers Squibb
Pfizer
Roche
Merck
Ono Pharmaceutical
Mylan
Fresenius Kabi
Sun Pharmaceuticals
Segment by Type
Pemetrexed
Cisplatin
Others
Segment by Application
Pleural Mesothelioma
Peritoneal Mesothelioma
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Malignant Mesothelioma Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Malignant Mesothelioma Therapeutic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Pemetrexed
1.2.3 Cisplatin
1.2.4 Others
1.3 Market by Application
1.3.1 Global Malignant Mesothelioma Therapeutic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Pleural Mesothelioma
1.3.3 Peritoneal Mesothelioma
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Malignant Mesothelioma Therapeutic Market Perspective (2019-2030)
2.2 Malignant Mesothelioma Therapeutic Growth Trends by Region
2.2.1 Global Malignant Mesothelioma Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Malignant Mesothelioma Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 Malignant Mesothelioma Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 Malignant Mesothelioma Therapeutic Market Dynamics
2.3.1 Malignant Mesothelioma Therapeutic Industry Trends
2.3.2 Malignant Mesothelioma Therapeutic Market Drivers
2.3.3 Malignant Mesothelioma Therapeutic Market Challenges
2.3.4 Malignant Mesothelioma Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue
3.1.1 Global Top Malignant Mesothelioma Therapeutic Players by Revenue (2019-2024)
3.1.2 Global Malignant Mesothelioma Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global Malignant Mesothelioma Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Malignant Mesothelioma Therapeutic Revenue
3.4 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio
3.4.1 Global Malignant Mesothelioma Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Malignant Mesothelioma Therapeutic Revenue in 2023
3.5 Malignant Mesothelioma Therapeutic Key Players Head office and Area Served
3.6 Key Players Malignant Mesothelioma Therapeutic Product Solution and Service
3.7 Date of Enter into Malignant Mesothelioma Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Malignant Mesothelioma Therapeutic Breakdown Data by Type
4.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Type (2025-2030)
5 Malignant Mesothelioma Therapeutic Breakdown Data by Application
5.1 Global Malignant Mesothelioma Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global Malignant Mesothelioma Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Malignant Mesothelioma Therapeutic Market Size (2019-2030)
6.2 North America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
6.4 North America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Malignant Mesothelioma Therapeutic Market Size (2019-2030)
7.2 Europe Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
7.4 Europe Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size (2019-2030)
8.2 Asia-Pacific Malignant Mesothelioma Therapeutic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2019-2024)
8.4 Asia-Pacific Malignant Mesothelioma Therapeutic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Malignant Mesothelioma Therapeutic Market Size (2019-2030)
9.2 Latin America Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
9.4 Latin America Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size (2019-2030)
10.2 Middle East & Africa Malignant Mesothelioma Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2019-2024)
10.4 Middle East & Africa Malignant Mesothelioma Therapeutic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly Malignant Mesothelioma Therapeutic Introduction
11.1.4 Eli Lilly Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Teva
11.2.1 Teva Company Detail
11.2.2 Teva Business Overview
11.2.3 Teva Malignant Mesothelioma Therapeutic Introduction
11.2.4 Teva Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.2.5 Teva Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Malignant Mesothelioma Therapeutic Introduction
11.3.4 Sanofi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.3.5 Sanofi Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Malignant Mesothelioma Therapeutic Introduction
11.4.4 Bristol-Myers Squibb Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Malignant Mesothelioma Therapeutic Introduction
11.5.4 Pfizer Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Roche
11.6.1 Roche Company Detail
11.6.2 Roche Business Overview
11.6.3 Roche Malignant Mesothelioma Therapeutic Introduction
11.6.4 Roche Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.6.5 Roche Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Malignant Mesothelioma Therapeutic Introduction
11.7.4 Merck Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Ono Pharmaceutical
11.8.1 Ono Pharmaceutical Company Detail
11.8.2 Ono Pharmaceutical Business Overview
11.8.3 Ono Pharmaceutical Malignant Mesothelioma Therapeutic Introduction
11.8.4 Ono Pharmaceutical Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.8.5 Ono Pharmaceutical Recent Development
11.9 Mylan
11.9.1 Mylan Company Detail
11.9.2 Mylan Business Overview
11.9.3 Mylan Malignant Mesothelioma Therapeutic Introduction
11.9.4 Mylan Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.9.5 Mylan Recent Development
11.10 Fresenius Kabi
11.10.1 Fresenius Kabi Company Detail
11.10.2 Fresenius Kabi Business Overview
11.10.3 Fresenius Kabi Malignant Mesothelioma Therapeutic Introduction
11.10.4 Fresenius Kabi Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.10.5 Fresenius Kabi Recent Development
11.11 Sun Pharmaceuticals
11.11.1 Sun Pharmaceuticals Company Detail
11.11.2 Sun Pharmaceuticals Business Overview
11.11.3 Sun Pharmaceuticals Malignant Mesothelioma Therapeutic Introduction
11.11.4 Sun Pharmaceuticals Revenue in Malignant Mesothelioma Therapeutic Business (2019-2024)
11.11.5 Sun Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
